Acrux Limited · ASX:ACR
Acrux — H1 FY2019 Earnings Presentation
15 slides from Acrux's earnings presentation, Feb 25, 2019
Slide 1: Acrux Investor Presentation and Half Year Results
For personal use only ACRUX INVESTOR PRESENTATION AND HALF YEAR RESULTS (ASX: ACR) February 2019
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS For personal use only This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Acrux to be mate
Slide 3: Investment Highlights
INVESTMENT HIGHLIGHTS For personal use only Attractive and • The topical generic market provides attractive returns with fast, low-risk development for drug developers accessible • The size of the topical generic market in the US alone worth ~US$18bn market Focus on • Acrux is deliberately focusing
Slide 4: Acrux has a clear strategy to create shareholder value
ACRUX HAS A CLEAR STRATEGY TO CREATE SHAREHOLDER VALUE For personal use only Acrux has deliberately targeted an ... and has built a scalable engine attractive, accessible and valuable focused on drug selection and market... development Multiple key advantages for targeting the topical generic market
Slide 5: Multiple key advantages for generic prescription product development
MULTIPLE KEY ADVANTAGES FOR GENERIC PRESCRIPTION PRODUCT DEVELOPMENT For personal use only Traditional development Acrux’s generic development portfolio Market size A new drug may have a significant market Attractive market and licensee terms opportunity, however… Speed …it takes ~10 years1 to devel
Slide 6: Acrux is operating in an attractive US$18bn market
ACRUX IS OPERATING IN AN ATTRACTIVE US$18bn MARKET For personal use only Total US prescription Topically applied pharma market prescription drug market Topical generics represent an attractive and significant market 12% 1 >US$400bn ~US$18bn2 opportunity 12% Other ✓ US$18bn market opportunity 4% Topi
Slide 7: Acrux pipeline represents a large market with relatively low competition
ACRUX PIPELINE REPRESENTS A LARGE MARKET WITH RELATIVELY LOW COMPETITION For personal use only Addressable market value1 ($USm) # of commercialised generic (ANDA) Addressable market competitors on the market 100 1,657 US$1.7 bn 4 Generics 42 17 Based on 14 products currently in the Acrux 3 Generics
Slide 8: Acrux has a focused strategy on drug selection and development
ACRUX HAS A FOCUSED STRATEGY ON DRUG SELECTION AND DEVELOPMENT For personal use only An illustrative pathway for generic drug development and commercialisation Status Description Identified topical 165 molecules, each with >US$10m in sales Market screening to identify high potential prescription top
Slide 9: Experienced management team with a proven history of meeting operational milestones
EXPERIENCED MANAGEMENT TEAM WITH A PROVEN HISTORY OF MEETING OPERATIONAL MILESTONES For personal use only Management team World class topical R&D team Michael Kotsanis BSc, MBus “I am extremely proud to lead an expert CEO & Managing Director topical drug development team. Our in- Experienced leader
Slide 10: Strategic direction led by a board with highly relevant expertise
STRATEGIC DIRECTION LED BY A BOARD WITH HIGHLY RELEVANT EXPERTISE For personal use only Michael Kotsanis Ross Dobinson CEO & Managing Director Non-Executive • Experienced leader in the pharmaceuticals industry with Chairman demonstrated success commercialising generic products Capital markets expert
Slide 11: Acrux continues to make progress across its key commercial objectives
ACRUX CONTINUES TO MAKE PROGRESS ACROSS ITS KEY COMMERCIAL OBJECTIVES For personal use only FY19 CY19 Acrux Submit 2 objectives dossiers to FDA Scale up 6 projects Add further First revenues from from Acrux products to generic generic portfolio in (in addition to FY18 laboratory to CMOs portfolio CY
Slide 12: Half Year Profit and Loss
HALF YEAR PROFIT AND LOSS Half Year Ending 31 December 31 December 2018 2017 For personal use only $'000 $'000 % Royalty revenue 275 2,420 (88.6%) Interest & other income 320 323 (0.9%) R&D tax incentive rebate 2,057 - - Total 2,652 2,743 (3.3%) R&D investment (4,926) (5,303) 7.1% Other operating co
Slide 13: Half Year Cashflow
HALF YEAR CASHFLOW Half Year Ending For personal use only 31 December 31 December 2018 2017 $'000 $'000 % Cash flow from operating activities Receipts from product agreements 254 6,570 (96.1%) Payments to suppliers and employees (6,571) (7,183) 8.5% Interest received 328 253 29.6% Income tax refunde
Slide 14: Corporate Overview
CORPORATE OVERVIEW For personal use only Trading Information Share price performance (last 12 months) Share price (as at 21 February 2019) A$0.180 Share price (A$) Volume (k) 0.40 8,000 Shares outstanding1 166.6m 0.35 7,000 Market capitalisation A$30.0m 0.30 6,000 Cash (as at 31 Dec 2018) A$22.2m Im
Slide 15: Thank You
For personal use only THANK YOU Investor enquiries Michael Kotsanis Anthony England Acrux Limited Vesparum Capital CEO & Managing Director Director P: + 61 3 8379 0100 P: + 61 3 8582 4800 E: michael.kotsanis@acrux.com.au E: Acrux@vesparum.com Visit our website: http://www.acrux.com.au/ Follow us on